https://www.ainvest.com/news/johnson-johnson-jnj-fgfr-inhibitor-erdafitinib-approved-domestic-2501/
Johnson & Johnson's (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for domestic use.
fgfr inhibitorjohnsonjnjuserdafitinib
https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-gastric-cancer-likelihood-of-approval/
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Gastric Cancer.
gastric cancererdafitinibjohnsonlikelihoodapproval